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Abstract: Recent studies indicate that corticotropin-releasing hormone (CRH) acts down-stream from brain melanocortin 
receptors (MC-Rs), however, much older evidence actually suggested the opposite. To reconcile this, rats were chroni-
cally infused centrally with the MC-R antagonist SHU9119 (0.5 nmol/day) over 14 days. Acute central CRH administra-
tion (0.5 μg) caused temporal anorexia, which was not impaired by SHU9119 treatment relative to controls. SHU9119 
treatment, however, did attenuate CRH-induced plasma ACTH and thermogenic responses. Since SHU9119 pair-fed rats 
showed generally similar effects as SHU9119-treated ad libitum feeding rats, the modulation of ACTH and thermogenic 
responses are not secondary to increased body weight by SHU9119 treatment. Central pre-treatment with the glucocorti-
coid receptor agonist dexamethasone (10 μg) before CRH demonstrated that the inhibitory effect of SHU9119 treatment 
on the CRH-induced ACTH response was not attributed to increased glucocorticoid feedback. Peripheral dexamethasone 
pre-treatment (25 μg/kg rat), on the other hand, more potently suppressed CRH-induced corticosterone responses in 
SHU9119-treated rats. This effect is explained by sensitization of the adrenal cortex to glucocorticoid feedback as a result 
of SHU9119 treatment. We conclude that MC-Rs act down-stream from CRH to facilitate CRH-induced HPA axis activa-
tion and thermogenesis, but not down-stream from CRH to facilitate anorexia. 
Keywords: Melanocortins, Obesity, Central nervous system, HPA-axis, CRH, GR 
INTRODUCTION 
 Corticotropin-releasing hormone (CRH) is an important 
regulatory component in the central nervous control of en-
ergy fluxes in the body [1, 2]. Within the hypothalamus, 
CRH is predominantly expressed in neuronal cell bodies 
located in the parvocellular division of the paraventricular 
hypothalamus (PVN). Among others, these neurons project 
to the median eminence (ME) where they secrete CRH into 
the hypophyseal portal circulation, from where CRH controls 
the release of adrenocorticotropic hormone (ACTH) from the 
anterior pituitary into the general circulation. In turn, this 
stimulates the secretion of glucocorticoids from the adrenal 
cortex [3]. The main glucocorticoid corticosterone (in ro-
dents) or cortisol (in man) serves many functions in periph-
eral fuel metabolism and endocrine activity of numerous 
organs [4]. In addition to being involved in pituitary hor-
mone secretion, a portion of these CRH neurons have been 
proposed to project to hindbrain and brain stem structures, 
which control autonomic outflow to the cardiovascular sys-
tem and several organs involved in fuel homeostasis [5,6].  
Finally, CRH is known to have acute [7] as well as pro- 
longed anorexigenic effects [8], and promotes body weight 
loss [8,9]. 
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 Consistent with a role for CRH in the regulation of en-
ergy fluxes in the body are reports suggesting that this neu-
ropeptide is implicated in the signaling cascade in the hypo-
thalamus of leptin [10]. Administration of leptin into the 
third cerebral ventricle (i3cv) upregulates the expression of 
CRH in this region [10], and stimulates labeling of c-Fos 
(i.e., a marker of neuronal activity) in CRH-containing neu-
ronal cell bodies in the PVN [11]. Furthermore, i3cv admini-
stration of the CRH antagonist -helical CRH over several 
days in mice prevents the effects of leptin on food intake and 
thermogenesis [12]. Besides CRH, also the brain melano-
cortin (MC) system is an important target of leptin in the 
CNS. For example, blockade of brain MC-Rs by i3cv ad-
ministration of the MC-R antagonist SHU9119 prevents 
leptin’s anorexigenic efficacy [13]. Because SHU9119 
treatment also markedly attenuated c-Fos labeling in PVN 
neurons, it was previously hypothesized that the brain MC 
system acts as an intermediairy system linking leptin signal-
ing to increased activation of CRH neurons. Consistent with 
this idea is the observation that i3cv infusion of the MC-R 
agonist, melanotan-II (MTII), causes reductions in food in-
take that can be blocked by co-administration of the CRH-
receptor antagonist, astressin [14]. The fact that CRH-
induced anorexia could not be blocked by co-administration 
of the MC-R antagonist HS014, suggests that MC-Rs only 
act upstream from CRH neurons [15]. By other measures, 
however, data in literature suggest that the MC system is 
acting down-stream from CRH neurons. For example, cen-
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tral administration of immunoglobulins raised against en-
dogenous MC-R ligands markedly reduced the thermogenic 
and metabolic responses to centrally administerd CRH in rats 
[16]. Furthermore, the data by Von Frijtag et al., [17] 
showed that central administration of SHU9119 in rats is 
able to blunt the ACTH response to foot shock stress. This 
could be explained by location of MC-Rs down-stream from 
CRH neurons. In order to reconcile the role of the MC sys-
tem in CRH effects, we aimed to investigate further effects 
of CRH on ingestive behavior, HPA axis activity (including 
glucocorticoid feed-back), thermogenesis, and non-ingestive 
behaviors in rats that were chronically i3cv infused with 
SHU9119 or saline. Because chronic SHU9119 treatment 
causes obesity, we also included a group of rats that were 




 Adult male Wistar rats, obtained from the breeding col-
ony maintained by the Center for Behavior and Neuro-
sciences at the University of Groningen and weighing be-
tween 400 and 450 g were used for the experiments. They 
were housed individually in Plexiglas cages (25x25x30 cm) 
on a layer of sawdust, in climate chambers under controlled 
temperature (22±2 
o
C), relative humidity (55-5 %) and main-
tained on a 12:12-h light-dark cycle (lights off 15:00-03:00 
hour). Animals were handled daily to minimize stress during 
experiments and weighed every day. The animals had ad 
libitum access to food (Hope Farms – Rat Mouse Hamster) 
and water except where noted. All methods and experiments 
were approved by the Animal Care Committee of the Uni-
versity of Groningen. Under isoflurane/N2O anesthesia, rats 
were implanted stereotaxically with a 22-gauge stainless-
steel guide cannula (Plastic One, Roanoke, VA, USA) into 
the third cerebral ventricle and one positioned into the left 
lateral cerebral ventricleaccording to Paxinos and Watson 
[18]. All other techniques can be found elsewhere [19]. After 
this procedure, animals had a biotelemetry transmitter im-
planted into the abdominal cavity, which allows online re-
cording of locomotor activity and body temperature (for 
methodology, see [19]). After surgery, each rat received a 
single injection of Finadine (0.1 ml/kg) for pain reduction 
and of natrium-benzyl-penicilline (100.000 IU), and rats 
were allowed to recover. After full recovery of pre-operative 
body weight, animals were implanted under isoflurane/N2O 
anesthesia with single jugular vein cannulas according to the 
methods described by Steffens [20]. Rats again received a 
single injection of Finadine (0.1 ml/kg) and a single dose of 
natrium-benzyl-penicilline (100.000 IU). Animals were al-
lowed to recover for at least ten days before the actual ex-
periments were started. During this period, placement of i3cv 
cannulas was verified by assessing the drinking response to 
Angiotensin-II, according to techniques described elsewhere 
[21]. 
Experimental Setup 
 After having stabilized food intake, body temperature 
and locomotor activity for at least 3 days, animals were im-
planted subcutaneously with osmotic minipumps (Alzet 
2002; Alza, Palo Alto, CA, pumping rate 0.55 μl/hour) under 
N2O-isoflurane anesthesia. Minipumps were connected with 
a polyethylene tube (PE50) to an injector permanently placed 
into the previously implanted i3cv guide canula. The pumps 
and tubing were filled to deliver either the aspecific 









]-cyclo--MSH (4-10) amide, M-4603, Sigma-
Aldrich Chemie GmbH, Sternheim, Germany, 0.5 nmol/day) 
or saline over a period of fourteen days. Assignment of rats 
to either i3cv SHU9119 (n=14) or saline (n=7) was such that 
the mean body weight among groups were similar. To ac-
count for food intake effects associated with reduced MC 
activity, half of the i3cv SHU9119-treated were pair-fed to 
the saline-treated control rats (n=7), whereas the others were 
allowed to feed ad libitum. Each pair-fed animal receiving 
SHU9119 was given the same amount of food consumed by 
the saline-treated rat to which it was paired based on body 
weight at the day of the minipump implantation (day 0). 
Pair-fed animals received food 3 times per day; i.e., at the 
onset of the dark phase, 4 hours later, and at the end of the 
dark phase, to maintain a relatively normal feeding schedule. 
 Starting one week before the experiment, body weight 
and food intake were assessed daily. At the end of the ex-
periment (day 14), animals were sacrificed by decapitation 
following brief CO2-anesthesia at approximately 3 hrs after 
lights on. Trunk blood was collected in ice-cooled borosili-
cate tubes containing 500 μl of aprotinin (10.000 IU/ml) and 
EDTA (0.05 g/ml). Thereafter, the abdominal cavity was 
opened, and retroperitoneal and epidydimal fat pads were 
isolated and weighed. Blood samples were centrifuged (15 
min, 2600 rpm, 4
o
C) and plasma samples were stored at –80 
o
C for determination of plasma levels of leptin, insulin, corti-
costerone and ACTH. Plasma levels of insulin, leptin and 
ACTH were measured by commercial radioimmunoassay 
kits (Linco Research; RI-13K, RL-83K and ACTH RIA kit, 
Nichols Institute Diagnostics, San Juan Capistrano, CA, 
USA). Plasma levels of corticosterone were measured using 
HPLC with UV detection according to Dawson et al., [22]. 
Effects of CRH on HPA-Axis Activity, Thermogenesis, 
and Locomotor Behavior 
 At days 7, 10, and 13 of the i3cv treatment, food hoppers 
were removed from the cages after light-onset. One-and-half 
hour later, rats were taken from their cage and shortly placed 
on the experimentor’s lap, where they received an lateral-
cerebroventricular infusion (ilcv) (over a 30 sec. interval) 
with dimethylsulfoxide (DMSO, vehicle, 1μl/rat) and an in-
traperitoneal (ip) injection of saline (0.5 ml). On one of these 
days (according to a semi-random design), the DMSO served 
as vehicle for the synthetic glucocorticoid dexamethasone 
(DEX; 9-fluoro-16-methyl-prednisolone, D-1756, Sigma-
Aldrich Chemie GmbH, Sternheim, Germany, 10 μg in 1 μl 
DMSO). On another day, not the ilcv injected DMSO, but 
the ip injected saline served as vehicle for DEX (25 μg/kg 
rat). The ip and ilcv doses of DEX have been shown to cause 
sub-maximal down-regulation of ACTH responses to treat-
ment with corticotropin-releasing hormone (CRH) [23]. On a 
third occasion, no DEX was added to the ip or ilcv injec-
tions, and thus served as control for the other conditions. 
Following these treatments, the ilcv cannula of rats was con-
nected to infusion tubing (PE 20, length 40 cm) of which the 
tip was filled with a solution of ovine CRH (American Pep-
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tide Company, Sunnyvale, California, USA), and they were 
connected to blood sampling tubing (PE 50, length 40 cm) as 
well. Rats were subsequently left in their cages undisturbed, 
with their blood sampling and infusion tubing externalized 
out of their cages such that blood sampling and/or ilcv infu-
sions could be performed remotely. Then, 1.5 hrs after injec-
tions (i.e, 3 hr after light onset), all animals were ilcv infused 
with CRH (0.5 μg dissolved in 1 μl saline during a 30-sec 
interval), with the exact time of infusion designated as t = 0. 
Relative to t = 0, blood samples (500 μl each) taken at t= -10, 
-1, 5, 15 and 60 minutes were collected in ice-cooled plastic 
tubes containing 50 μl of aprotinin, 10.000 IU/ml and EDTA 
0.05 g/ml. After centrifugation (15 min, 2600rpm, 4 
o
C) 
plasma samples were stored at –80 
o
C for determination of 
plasma concentrations of ACTH and corticosterone. To 
avoid a decrease in total blood volume, each animal received 
0.5 ml of sterile saline after each blood sample was taken. 
Food hoppers were returned to the rat cages 2 hrs after CRH 
injection. 
 Whereas the effects of ilcv infusion of CRH on HPA axis 
activity were assessed under conditions of peripheral, cen-
tral, and no DEX pre-treatment, the effects of ilcv-infused 
CRH on body temperature and spontaneous activity were 
only assessed in the condition without DEX pre-treatment. 
During the 2 hours before CRH infusion, and until 2 hrs after 
infusion, average body temperature over 5-min periods and 
cumulative spontaneous activity over two hours were as-
sessed with the Data-Quest Biotelemetry system. 
Effects of CRH on Ingestive Behavior 
 Different groups of rats only equipped with combined 
i3cv- and ilcv-cannulation, but without blood sampling 
catheters and biotelemetry transmiters, were either given 
minipumps filled to deliver i3cv saline (n=5) or SHU9119 
(0.5 nmol/day, n=6) according to the same techniques men-
tioned above. Experiments were conducted after food intake 
in the i3cv SHU9119-treated rats stabilized at a higher level. 
On two separate days with at least 3 days between successive 
experiments, food hoppers were removed from the cages 2 
hrs before the onset of the dark phase and returned to the 
cages at lights off. One hour before the dark phase on these 
days, rats were ilcv infused with saline (1 μl) or CRH (0.5 
μg/μl saline) according to a latin-square design, allowing 
each animal to act as its own control. Weight of food hop-
pers was assessed just before returning to them to the cages 
(at lights off, t=0 hr), and also at t=4, 12 and 24 hrs. At the 
end of i3cv treatment periods, rats were anaesthetized 3 hrs 
after lights on, and decapitated. Brains were removed and 
frozen on crushed dry ice, and stored at –80 
o
C until being 
cut on a cryotome for assessment of canula placements 
(which were all correct). 
Statistical Analysis 
 Results are presented as means ± SEM, repeated meas-
ures analysis of variance (ANOVA) was used to assess tem-
poral and treatment effects on food intake and body weight, 
and on neuroendocrine and thermogenic responses of CRH. 
One-way ANOVA was used to assess treatment effects on 
end-point neuroendocrine and metabolic parameters. Data 
were considered significant if levels of p < 0.05. 
RESULTS 
Effects of i3cv SHU9119 Treament on Body Weight and 
Food Intake 
 The effects of i3cv SHU9119 and saline treatment on 
body weight and food intake of rats are shown in Fig. (1). 
Results are depicted as % change compared to average body 
weight or food intake of days -1 and 0. Food intake in the 
i3cv SHU9119-treated animals was already significantly 
increased (p<0.05) on the first day following pump-
implantation relative to saline-treated controls. This differ-
ence in food intake became larger each next day until a pla-
teau of about 200% of initial intake was reached at day 7. 
Significant increases in body weight (p<0.05) were found in 
i3cv SHU9119-treated rats from day 5 on. Body weights of 
i3cv SHU9119-treated rats that were pair-fed to saline-
treated rats were indifferent from saline-treated animals. 
Relative to i3cv saline treatment, the effects of i3cv 
SHU9119 treatment on body weight were associated with 
increases in retroperitoneal and epidydimal fat pad weight, 
and elevated plasma leptin and insulin levels. No differences 
were found in the level of circulating corticosterone. Consis-
tent with previous findings [19] were the observations that 
i3cv SHU9119 treatment increased abdominal fat weight and 
 
Fig. (1). Changes in body weight (left panel) and food intake (right panel) in rats that were either i3cv infused with saline (Control, n=7) or 
SHU9119 (SHU, n=7). A third group consisted of i3cv SHU9119-treated rats were pair-fed to saline-treated controls (SHUpf, n=7). 
Minipump-implantation was performed on day 0. Results are depicted as % change compared to baseline. Asterisks denote sigificant differ-
ences (p<0.05) compared to controls. 
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plasma leptin levels when these animals were pair fed to 
saline-treated controls, and plasma levels of insulin were 
only elevated in SHU9119-treated ad libitum feeding rats 
(see Table 1). 
Effects of i3cv SHU9119 Treatment on CRH-Mediated 
Stimulation of Thermogenesis and Locomotor Behavior 
 Effects of ilcv CRH administration on body temperature 
in the i3cv saline and i3cv SHU9119-treated groups are 
shown in Fig. (2). The insert in Fig. (2) shows the basal av-
erage body temperature over 2 hr prior to the ilcv CRH infu-
sion, indicating that there was no difference among the i3cv 
saline, i3cv SHU9119 ad libitum and i3cv SHU9119 pair-fed 
rats. Ilcv CRH infusion (at t=0 min) caused significant in-
creases (p<0.05 from t= 60 min onwards) in body tempera-
ture relative to baseline in i3cv saline-treated rats, an effect 
that was not observed in both i3cv SHU9119-treated groups 
of rats. Moreover, i3cv SHU9119-treated ad libitum feeding 
rats had significantly lower body temperature over time 
(from t=0 – 120 min) following ilcv CRH infusion than i3cv 
saline-treated rats (p<0.05). The difference between i3cv 
saline-treated and i3cv SHU9119-treated pair-feeding rats 
did not attain statistical significance.  
 The effects of ilcv CRH administration in the three i3cv 
treatment groups on cummulative locomotor activity are 
shown in Table 2. All comparisons of basal and CRH-
stimulated changes of locomotor activity in i3cv SHU9119-
treated groups (ad libitum or pair-feeding) relative to the 
i3cv saline-treated group did not attain significance. How-
ever, basal cummulative locomotor activity over 2 hrs prior 
to ilcv CRH administrationwas significantly higher (p<0.05) 
in the i3cv SHU9119 pair-feeding rats than in the i3cv 
SHU9119 ad libitum feeding rats. The percentual increase in 
cummulative locomotor activity following i3cv CRH ad-
ministration relative to baseline, tended (p=0.06) to be in-
creased in the i3cv saline-treated rats relative to i3cv 
SHU9119-treated ad libitum feeding animals. 
Effects of i3cv SHU9119 Treatment on CRH-Mediated 
Stimulation of HPA-Axis Activity 
 Effects of ilcv CRH administration on plasma ACTH 
levels of rats in the different chronic i3cv treatment groups 
are shown in Fig. (3). Relative to controls, i3cv SHU9119-
treated pair-fed rats had a markedly suppressed ACTH re-
sponse following ilcv CRH administration. There was also a 
slight decrease in i3cv SHU9119-treated ad libitum feeding 
animals, but this reduction did not attain statistical signifi-
Table 1. Plasma concentrations of leptin and insulin, and weights of abdominal fat pads (total of retroperitoneal and epidydimal 
fatpads) of rats at the end of 14-day i3cv treatment with saline (Control, n=7) or SHU9119 (SHU, n=7). A third group of 
rats was i3cv-infused with SHU9119, but were pair-fed (SHUpf, n=7) to saline-treated controls.  
Treatment Control SHU SHUpf 
Leptin (ng/ml) 2.98±0.47 30.65±3.10*** 6.14±0.67* 
Insulin (ng/ml) 2.63±0.16 9.82±1.11** 3.30±0.38 
Abd. fat pads (g) 7.44±0.49 17.60±1.35** 9.39±0.66* 
Values depicted as means ± SEM. * p<0.05, ** p<0.01 and ***p<0.001 compared to vehicle-treated controls. 
 
Fig. (2). Effects of CRH administration (0.5 μg, t=0) on body temperature (Celcius) of i3cv saline-treated rats (open circles, n=7), i3cv 
SHU9119-treated rats (black triangles, n=7), and i3cv SHU9119-treated rats pair-fed to controls (black squares, n=7). The effects of CRH 
administration on body temperature are presented as change from t=0 min [Delta T(ºC)]. The insert shows average temperature over a period 
of 2 hrs prior to CRH administration in the three i3cv treatment groups. Values are depicted as means ± SEM.  
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cance. In order to investigate whether the decreased ACTH 
response was due to increased glucocorticoid feedback, ilcv 
CRH effects on plasma ACTH responses were also per-
formed with prior ilcv (Fig. 3b) and ip (Fig. 3c) DEX treat-
ment. In both DEX pre-treatment conditions, ACTH re-
sponses were suppressed relative to the situation without 
DEX pretreatment. Under the conditions of ilcv (Fig. 3b) or 
ip (Fig. 3c) DEX pretreatment, however, CRH-induced 
ACTH responses were not more potently suppressed in i3cv 
SHU9119-treated rats compared to the i3cv saline-treated 
control group.. In fact, in the ip DEX condition, ACTH lev-
els in the i3cv SHU9119-treated ad libitum feeding animals 
were higher relative to the controls (significantly elevated at 
t=5 min, p<0.05), demonstrating a reduced suppression of 
ACTH level by DEX in i3cv SHU9119-treated animals rela-
tive to i3cv saline treatment. 
 Effects of ilcv CRH administration on plasma corticos-
terone levels of rats in the different chronic i3cv treatment 
groups are shown in Fig. (4). Unlike the differences of 
plasma ACTH responses among groups without DEX pre-
treatment, ilcv CRH administration in rats in the three differ-
ent i3cv treatment groups caused similar increases in plasma 
levels of corticosterone (Fig 4a). Central (Fig 4b) as well as 
peripheral (Fig 4c) DEX pre-treatment generally caused re-
ductions in plasma corticosterone levels upon ilcv CRH ad-
ministration compared to non-DEX treated rats. These reduc-
tions were largely attributed to a fall in plasma corticoster-
one level already at baseline (t=-11 and –1 min). Whereas 
the corticosterone responses following ilcv CRH administra-
tion were not different among the i3cv treatment groups with 
ilcv DEX pre-treatment, plasma levels of corticosterone in 
the ip DEX pre-treatment group following ilcv-administered 
CRH were significantly reduced in the i3cv SHU9119-
treated ad libitum feeding (at t=15 min) and i3cv SHU9119-
treated pair-fed (at t=60 min) rats relative to controls. 
 To assess the magnitude by which DEX was able to sup-
press ACTH and corticosterone responses to ilcv CRH ad-
ministration relative to the condition without DEX pre-
treatment, area-under-the-curves (AUCs) of plasma ACTH- 
and corticosterone responses were expressed as % suppres-
sion compared to vehicle pre-treatment. These relative sup-
pressions by DEX of plasma ACTH- and corticosterone lev-
els are depicted in Fig. (5). Rats receiving chronic i3cv 
SHU9119 treatment had significantly reduced suppression of 
the CRH-mediated ACTH response by ilcv DEX pre-
treatment, and a near-significantly (p=0.07) reduced suppres-
sion following ip DEX pre-treatment (Fig. 5A). In the case 
of the corticosterone response to ilcv-infused CRH, ip DEX 
pre-treatment produced a stronger suppression (p<0.05) in 
the i3cv SHU9119-treated pair-feeding rats, and a near-
significantly stronger (p=0.06) suppression in the i3cv 
SHU9119-treated ad libitum feeding rats relative to i3cv 
saline-infused controls (Fig. 5B). CRH-mediated increases in 
plasma corticosterone levels were not (differently) sup-
pressed by ilcv DEX treatment. 
Table 2. Cumulative locomotor activity during 2 hr basal and 2 hr post CRH administration (0.5 μg) as well as percentual (%; 
[Post/Basal]x 100) increases in locomotor activity in i3cv saline-treated rats (Control, n=7), i3cv SHU9119-treated rats 
(SHU, n=7), or i3cv SHU9119-treated rats pair-fed to controls (SHUpf, n=7).  
Treatment Control SHU SHUpf 
Basal 171.8±29.4 111.7±33.5 295.5±27.4* 
Post 729.4±144.0 216.5±85.5 666.3±152.5 
% 424.6±77.5 193.8±24.5 225.5±39.7 
Values depicted as means ± SEM. Asterisks denote p<0.05 compared to SHU9119-treated ad libitum feeding rats.  
 
Fig. (3). Plasma ACTH levels in rats after CRH administration (0.5 μg, t=0) that were chronically i3cv infused with saline (Control, n=7), 
SHU9119 (SHU, n=7), or SHU9119 but pair-fed to saline-treated controls (SHUpf, n=7). Before CRH administration, all rats were either 
pre-treated with vehicle (panel A) or dexamethasone given centrally (panel B) or dexamethasone given peripherally (panel C). Values de-
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Effects of i3cv SHU9119 Treatment on CRH-Mediated 
Anorexia 
 In different i3cv saline-treated and i3cv SHU9119-treated 
animals as those used above, the effect of ilcv CRH admini-
stration was investigated on food intake relative to ilcv-
infused saline. The effects of i3cv SHU9119 treatment and 
i3cv saline treatment on food intake and body weight were 
comparable to those mentioned above. The anorexigenic 
effects of CRH relative to saline were assessed when food 
intake in the i3cv SHU9119-treated rats stabilized at a high 
level; i.e., between days 7 and 11 of treatment. Since food 
intake in the i3cv SHU9119-treated rats was much larger 
relative to i3cv saline-treated controls, food intake suppres-
sion by ilcv CRH infusion was indicated as a percentual re-
duction from ilcv saline infusion (Fig. 6). It was observed 
that the percentual suppression of food intake at 4 hrs in the 
dark phase by CRH in the i3cv SHU9119-treated rats was at 
the threshold of being significantly larger than that in the 
i3cv saline-treated rats (p = 0.05). At t=12 and t=24 hours, 
no differences were observed between groups (data not 
shown).  
DISCUSSION 
 Administration of CRH into the cerebral ventricular sys-
tem of rats caused marked reductions in food intake and in-
creases in body temperature, locomotor activity, and in-
creased activity of the HPA axis. These responses are pre-
sumably mediated by CRH acting on post-synaptic CRH1 
and CRH2 receptors in several projection sites, but also by a 
stimulatory effect on paraventricular hypothalamic CRH 
neurons, from which many of these projections originate 
[24,25]. The present study investigated the involvement of 
brain melanocortin receptors (MC-Rs) in these responses. 
We therefore investigated the effects of lateral cerebroven-
tricular (ilcv) CRH infusion on above-mentioned parameters 
in rats that were chronically infused into the third cerebral 
ventricle (i3cv) with the unspecific MC3/4-R antagonist, 
SHU9119, and in i3cv saline-treated controls. Overall, the 
effects of MC-R antagonism on CRH-induced changes in 
food intake, HPA axis activity and body temperature were 
not secondary to increased body weight, since i3cv 
SHU9119-treated rats pair-fed to controls generally showed 
similar responses as i3cv SHU9119-treated rats fed ad libi-
 
Fig. (4). Plasma corticosterone levels in rats after CRH administration (0.5 μg, t=0) that were chronically i3cv infused with saline (Control, 
n=7), SHU9119 (SHU, n=7), or SHU9119 but pair-fed to saline-treated controls (SHUpf, n=7). Before CRH administration, all rats were 
either pre-treated with vehicle (panel A), dexamethasone given centrally (panel B), or dexamethasone given peripherally (panel C). Values 
are depicted as means ± SEM. Asterisks denote p<0.05 compared to controls. 
 
Fig. (5). Relative suppression of plasma ACTH responses (panel A) and plasma corticosterone responses (panel B) after central (Dex lv) or 
peripheral (Dex ip) dexamethasone pre-treatment in response to CRH administration (0.5 μg) in rats with i3cv saline treatment (Con, n=7), 
i3cv SHU9119 treatment (SHU, n=7) or i3cv SHU9119 treatment and pair-fed to controls (SHUpf, n=7). Values depicted as means ± SEM. 
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tum. With respect to food intake, we could reinforce the find-
ings by Vergoni et al., [15] that MC-R blockade does not 
impair the anorexigenic efficacy of CRH. In fact, we found 
that i3cv SHU9119-treated rats had a strong tendency to-
wards being more sensitive to the anorexigenic effects of 
CRH over the first few hours in the dark phase. Such an ef-
fect was previously observed in mice with a targeted muta-
tion in the DNA encoding for MC-R4 as well [26], and 
would be consistent with the notion that CRH neurons nor-
mally receive stimulatory input from MC neurons under 
conditions of a positive energy balance. With respect to HPA 
axis activity and thermogenesis, a completely different pic-
ture emerged on the contribution of MC-Rs in CRH effects. 
In light of our previous findings that i3cv SHU9119-treated 
rats have an increased expression of CRH in PVN neurons 
[19], ilcv CRH injection might have been expected to cause 
increased thermogenesis [6,7] and HPA axis activity [14]. 
However, the plasma ACTH response and the increase in 
body temperature following CRH were markedly suppressed 
in i3cv SHU9119-treated rats. The finding that CRH-
mediated thermogenesis is impaired by central immunoneu-
tralization of proopiomelanocortin precursors is in agreement 
with our findings [16]. One possible mechanism explaining 
these effects is that MC-Rs are located on synaptic terminals 
of CRH neurons in the ME and sympathetic brain 
stem/spinal cord regions involved in thermogenesis, and that 
tonic activity on these MC-Rs is required for increased CRH 
release or action in the ME and brain stem/spinal cord. 
While the presence of the MC-Rs on CRH terminals (either 
pre-or post-synapticaly) has not yet been identified, there is 
evidence that neuronal fibers containing CRH and those that 
contain melanocortins are closely associated in forebrain as 
well as hindbrain regions [27], allowing us to speculate that 
such an interaction may indeed exist.  
 Another mechanism by which MC-R blockade could 
potentially blunt CRH-mediated increases in plasma ACTH 
levels is that glucocorticoid feedback is increased in i3cv 
SHU9119-treated rats. This mechanism could potentially 
also account for reduced CRH-mediated thermogenesis in 
i3cv SHU9119-treated rats [28]. To investigate whether in-
creased glucocorticoid feedback underlies the observed phe-
nomena on CRH-induced activation of ACTH release, ilcv 
CRH effects on ACTH responses were investigated with 
central as well as peripheral pre-treatment of the synthetic 
glucocorticoid receptor (GR) agonist, dexamethasone 
(DEX). Opposite to a potential upregulation of glucocorti-
coid feedback explaining the lower CRH-induced ACTH 
response, however, we observed that the degree of suppres-
sion by central DEX on the CRH-mediated ACTH response 
was significantly reduced in i3cv SHU9119-treated rats. In 
support of these findings is our recent observation that i3cv 
SHU9119-treated rats have a significant reduction in GR 
density in the PVN (van Dijk et al. in preparation). Down-
regulation of GR in the PVN would imply an increased ex-
pression of CRH mRNA in the PVN [29], and that is exactly 
what we previously found in i3cv SHU9119-treated rats 
[19]. These data are also consistent with the findings by 
Rigter et al., [30] showing that MC-R activation upregulates 
GR binding sites in several brain regions. In addition, how-
ever, we found that the CRH-mediated ACTH response ap-
peared to be near-significantly suppressed upon peripheral 
DEX pre-treatment. This indicates that GR feedback at the 
level of the pituitary would be lower in SHU9119-treated 
rats. Since i3cv SHU9119-treated pair-fed rats did not show 
any down-regulation of GR feedback with plasma ACTH as 
read-out parameter, the action by which i3cv SHU9119 
treatment causes these effects is probably indirect. It might 
be argued, for example, that leptin being elevated in the 
SHU9119-treated ad libitum feeding rats, causes a down-
regulation of GR. Although leptin has previously been 
shown to upregulate PVN GR density and expression in the 
neonatal stage [31], opposite effects on GR density in the 
neonatal vs. adult rat have previously been reported for other 
treatments (e.g., [32,33]).  
 Despite the reduction of the CRH-induced plasma ACTH 
response in i3cv SHU9119-treated rats relative to controls, 
this did not result in lower plasma levels of corticosterone. 
When lower levels of ACTH result in similar corticosterone 
responses, this would imply that reduced melanocortin 
transmission increases the sensitivity of the adrenal cortex to 
ACTH, perhaps analogous to a mechanism previously des-
ribed by Buijs et al., [34]. If any, this effect must be quite 
robust since the hyperleptinemia in i3cv SHU9119-treated 
rats would normally oppose glucocorticoid secretion [35] 
(but see [11,33]). As opposed to the reduced suppression by 
DEX of the CRH-induced ACTH responses in i3cv 
SHU9119-treated rats, peripheral DEX pre-treatment caused 
a markedly enhanced suppression of the CRH-mediated cor-
ticosterone response in i3cv SHU9119-treated rats, irrespec-
tive of pair-feeding or ad libitum feeding. These effects were 
not observed with central DEX pretreatment. Although we 
are not aware of any study assessing the presence of GR in 
the adrenal cortex, this would imply that endogenous corti-
costerone may potentially down-regulate its own release 
more potently through such an ultra-short feed-back loop in 
animals i3cv treated with SHU9119. Collectively, these 
mechanisms would attenuate the activity of the HPA axis in 
animals with i3cv SHU9119 treatment, despite upregulated 
expression of CRH that we previously found with SHU9119 
treatment [19]. 
 Taken together, chronic blockade of MC receptors does 
not inhibit CRH-induced anorexia, but blunts CRH-induced 
thermogenesis and HPA axis activity. These data therefore 
 
Fig. (6). Percentual suppression of 4-hr food intake after CRH ad-
ministration (0.5 μg) in rats that were chronically i3cv infused with 
saline (Con, n=5) or with SHU9119 (SHU, n=6). Data are ex-
pressed as % suppression of food intake by CRH relative to saline 
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indicate that MC receptors act downstream from CRH ef-
fects on ACTH release and thermogenesis, but not down-
stream from CRH effects on feeding. This study additionally 
demonstrates that increased GR feed-back is not responsible 
for the reduced efficacy by which CRH can increase plasma 
ACTH levels in i3cv SHU9119-treated rats, but increased 
GR feedback in i3cv SHU9119-treated rats at the level of the 
adrenal cortex could limit glucocorticoid secretion on the 
long-term. We propose that - in addition to be located on 
CRH-containing neuronal cell bodies in the PVN [14], and 
which may be involved in feeding behavior- MC-Rs may 
also be present on neuronal terminals (either pre- or post-
synaptically, or both) where they can fine-tune the stimula-
tory effect of CRH on ACTH release. Such an effect may be 
anticipated for CRH-induced thermogenesis via sympathetic 
preganglionics as well. Indeed, melanocortin receptor activ-
ity has been associated with regulation of sympathetic tone 
[36], which is an important mechanism to stimulate ther-
mogenesis. Thus, the effects of SHU9119 on CRH respon-
siveness may involve suppression of MC-R’s stimulatory 
effect on sympathetic outflow, for instance at the level of the 
adrenal gland and brown adipose tissue, but apparently not 
for CRH-induced anorexia. The function of this dissociation 
is yet unknown, but considering the fact that the endogenous 
inverse agonist agouti-related protein (AgRP) could serve 
similar actions as SHU9119 [37], and mutations in MC-R4s 
are found relatively frequently at least in the human popula-
tion [38], the proposed regulatory influences of MC-R activ-
ity on CRH efficacy might have adaptive behavioral and 
physiological relevance. Such relevance may be found, for 
example, in situations in which an emotional/physical stres-
sor calls forth a temporal activation of the CRH system in 
thrifty animals due to low activity of the MC system. Ac-
cording to the data in the present study, this would be ex-
pected to induce a strong CRH-mediated decline of energy 
intake (for example, necessary to focus on external stimuli, 
rather than on feeding), but at the same it would minimize 
wasting of energy through reduced efficacy of CRH to 
stimulate thermogenesis and HPA axis activity. 
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